Categories
Rankings Update

Mid-Week Rankings Update – 05/28/2020

Hello, and welcome to this week’s rankings update. It has been a rather quiet week in the psychedelics sphere, at least in comparison to the past month.

MindMed (MMEDF) had a relatively eventful week, however, after closing an upsized financing deal to pursue “next-gen psychedelic inspired medicines.” The company also announced that it was adding MDMA to these so-called “psychedelic inspired” therapies. In my humble opinion, I wouldn’t describe MDMA and LSD as “inspired by psychedelics” so much as I would just describe them as outright psychedelics. While the buzz-worded press releases we have received from these firms generally serve no purpose but to boost the stock, MindMed maintains their position near the top of the Mind Altering Index.

Numinus (NUMI) has now dethroned Champignon Brands from the number one spot, elevated by increasing popularity and management strength. This increase in management strength is owed directly to the company’s new Chief Medical Officer, Dr. Evan Wood. Numinus announced May 21 that they hired Dr. Evan Wood for the new position of CMO. This announcement comes only one day after the firm’s Reverse Takeover on the Toronto Stock Exchange, in which shares of the company were offered to the public for the first time.

Dr. Wood is a valuable addition to Numinus’ management team, as he brings a perfect score in all three ranking categories. Dr. Wood has extensive experience in the biopharmaceutical industry and was involved in the Multidisciplinary Association for Psychedelic Studies’ research on MDMA for treating a variety of mental disorders. He was also involved with MAPS for research involving psilocybin psychotherapy. These qualifications will be useful as Numinus seeks to bring psychotherapeutics to a broad market. The company’s management strength score increased about 13%, securing their position in first place of the Mind Altering Index.

The new rankings of the Mind Altering Index are as follows:

  1. Numinus Wellness: 0.69
  2. Champignon Brands: 0.66
  3. MindMed: 0.66
  4. Revive Therapeutics: 0.46
  5. New Leaf Brands: 0.44
  6. Hollister Biosciences: 0.3

The Mind Altering Index website will be updated accordingly with a breakdown of each score. Please check MindAlteringIndex.com/Psychedelic-Stocks/ for updated scores and analysis.

Categories
Management Team Change

Numinus Hires Chief Medical Officer

Numinus (NUMI) announced today that they have hired Dr. Evan Wood for the new position of Chief Medical Officer. This announcement comes only one day after the firm’s Reverse Takeover on the Toronto Stock Exchange, in which shares of the company were offered to the public for the first time.

Dr. Wood is a valuable addition to Numinus’ management team, as he brings a perfect score in all three ranking categories. Dr. Wood has extensive experience in the biopharmaceutical industry and was involved in the Multidisciplinary Association for Psychedelic Studies’ research on MDMA for treating a variety of mental disorders. He was also involved with MAPS for research involving psilocybin psychotherapy. These qualifications will be useful as Numinus seeks to bring psychotherapeutics to a broad market. The company’s management strength score increased about 13%, securing their position in the top half of the MAIpsyc. The overall MAIpsyc score is now 0.643 as a result. The website will be updated accordingly.

Categories
Investing

How to Trade Numinus Wellness Stock

Numinus (NUMI) commences public trading today.

Now that Numinus Wellness is a publicly traded company, you may be wondering how to get in on the action. Numinus is listed on the Toronto Stock Exchange, within their Venture Exchange subsidiary. It can be found on Canadian brokers with the ticker V.NUMI. On American brokers, you can find the company with the ticker LKYSF or LKYSD (Ameritrade).

Yes, it is possible to purchase Numinus stock today through your American broker. If you are unable to find the ticker, give your broker a call in order to make the trade.

Numinus’ public offering is an exciting opportunity in the psychedelic industry, and after a strong open, the company seems to have retreated to a more stable level. At the time of this writing, the company is trading at $0.71 per share, and if it remains at this level, we can imagine that the Mind Altering Index may change once again in the coming days.

Categories
Rankings Update

Mid-Week Rankings Update – 05/20/2020

It’s Wednesday my dudes! That means it’s time for our second mid-week rankings update. If you thought last week was eventful for the psychedelics industry, the craze has only gained momentum since. Although there haven’t been major management team changes, a lot has happened across the industry.

Disclaimer: none of the information in this alert constitutes professional investing advice. We have not been paid to promote any of the companies listed. Please consult a registered financial advisor before making investment decisions.

New Leaf Brands (NLBIF0.426 MAIpsyc) reached its six-month high on Monday, a whopping 22,388% increase from its yearly low on March 20, before retreating 17.52% during Tuesday trading. Despite these impressive gains, NLBIF’s MAIpsyc score has remained rather stagnant, as the company has not provided a substantiative progress update recently.

NLBIF’s strong month

Champignon Brands (SHRMF0.698 MAIpsyc) announced Monday it was sponsoring TheraPsil, a non-profit coalition aiming to improve psilocybin access for palliative cancer patients. This appears to be an intelligent strategic move to increase government acceptance of psychedelic therapies, thus improving the legislative environment. Champignon has had a similarly impressive month, and, unlike NLBIF, does not appear to be losing any steam. With their market cap soaring to around $140 million, Champignon has claimed first place in the MAIpsyc index with an overall score of 0.698, replacing MindMed.

SHRMF’s strong month

In anticipation of their RTO scheduled for Wednesday morning, we have added Numinus (NUMI0.612 MAIpsyc) to the MAIpsyc with an introductory score of 0.612! NUMI immediately claimed first place in this week’s popularity rankings, and it performs well in the focus degree category. The stock will be listed on the TSXV (Toronto Stock Exchange Venture). If you are an American investor, you may be able to purchase NUMI shares at market open. Call or email your stock broker to ensure this is possible. If not, certain brokers may be able to make trades on your behalf over the phone.

Revive Therapeutics (RVVTF0.439 MAIpsyc) has performed strongly this week, closing at nearly double week-over-week on Tuesday. Revive is hoping to embark on phase 3 of clinical trials for Bucillamine in the treatment of mild to severe COVID-19 cases, in addition to the progress they are making in psilocybin research.

MindMed (MMEDF0.634 MAIpsyc) has remained rather stagnant, despite a strong week across the board for MAIpsyc companies. The company hasn’t published a press release in more than a week. As a result of its weak performance against peers, as well as the addition of Numinus, MindMed has lost its first place position in the MAIpsyc.

Hollister Biosciences (HSTRF0.294 MAIpsyc) has also stayed mostly stagnant, hovering around the $0.08 price point.

Mind Altering Index News

Our team has been working tirelessly to perfect the Mind Altering Index. We have exciting announcements in the pipeline, and the MAIsubscriber Base will be the first to receive the alerts. We look forward to becoming an integral part of the psychedelic investing community.

Categories
Rankings Update

Mid-Week Rankings Update – 05/13/2020

It’s Wednesday my dudes! That means it’s time for our first mid-week rankings update. It has been an active week for the MAIpsyc, and the ‘Shroom Boom’ is continuing to gain momentum. Several companies adjusted their management teams and announced bought deal financing, and New Leaf Brands is up more than 200% on the week. We have begun the process of adjusting the algorithm with these new data, and we have created a new overview of the MAIpsyc.

Disclaimer: none of the information in this alert constitutes professional investing advice. We have not been paid to promote any of the companies listed. Please consult a registered financial advisor before making investment decisions.

MAIpsyc rankings as of May 12, 2020
MAIpsyc rankings as of May 13, 2020

From this macro perspective, it appears that nothing much has changed. Let’s dive into the details, and you will see that this is not quite the case.

Big Movers

  • MindMed’s Overall MAIpsyc decreased by about 5 points, as a result of a slightly lower popularity factor as well as a slight decrease in focus degree relative to peers. This is merely a reflection of the moves of its competitors, especially Champignon Brands, to hire relevant experts.
  • New Leaf Brands increased by 3 points. This is due to the higher market cap factor as a result of the dramatic gains this week. Popularity, management strength, and market cap all increased this week.

MMEDF – Decrease in popularity and focus degree, resulting in lower Overall MAIpsyc

The Week Ahead

Many firms within the MAIpsyc have recently announced bought deal financing. While this may dilute current shareholders, it shouldn’t be viewed negatively. Large financing rounds will be required to fund expensive clinical trials, and thus should be expected. With the precedent set by cannabis legalization, it should not come as a surprise if every MAIpsyc company eventually announces bought deal financing. Thus, this week’s focus degree has been improved by including calculations related to this type of financing.

Microdose is hosting a fireside chat tonight at 7PM EST with Paul Glavine, CEO and Co-Founder of Cybin, Corp. “Cybin Corp is a Mushroom Life Sciences company advancing psychedelic and medicinal mushroom research, product development and IP through a multi-tiered pharmaceutical and nutraceutical approach.” Tickets are free and available here.

The Mind Altering Index is working rapidly to improve our algorithm, and although we recognize it is far from perfect right now, we hope to have a reliable system in place within the next week. We are also coding a webapp to ease the process of updating the site’s data. Site-wide MAIpsyc scores will be updated this evening, and hopefully this is the last time we will have to do it manually!

Thank you for reading, and thank you for subscribing to the MAIsubscriber Base. We are happy to have you 🙂

Categories
Management Team Change

New Leaf Brands Hires CSO – 05/12/2020

New Leaf Brands, the CBD company that has recently made a strategic pivot toward psychotherapeutics, has announced a new executive role: Chief Science Officer. To fill the position, they hired Rob Roscow, the former research director at Ebbu, a cannabinoid research and technology firm. Roscow also served as the lead director of genetic research at Canopy Growth, as well as the co-founder of Mydecine Group.

Roscow brings valuable industry experience to the New Leaf Brands management team, further solidifying their legitimacy in the psychedelic medicine industry. Adding the role of Chief Science Officer was a necessary move to keep up with competitors, and this has positively impacted New Leaf’s MAIpsyc score.

Previous concerns about New Leaf Brand’s focus degree have been reduced as a result, as it is clear that they are intending to materially advance psychedelic research. They have evolved from a CBD brand dabbling in psychedelics to a company attempting to “unlock the medical potential in mushroom compounds.”

New Leaf Brands MAIpsyc score will be updated as a result of this change.

Categories
Management Team Change

New CEO at Champignon Brands – 05/11/2020

SHRMF – 0.675 MAIpsyc

Champignon Brands announced today that they have hired Dr. Roger McIntyre as the new CEO. This replaces the former CEO, Gareth Birdsall. This comes just five days after the company’s previous announcement to appoint Pat McCutcheon to the board, as well as a decision to keep Birdsall for the time being. Gareth Birdsall had extensive experience within the biopharmaceuticals industry, and he remains on the board of directors.

Fortunately, Dr. McIntyre also has extensive experience in the biopharmaceuticals industry. He worked for nearly eighteen years at the University Health Network, specializing in the Mood Disorders Psychopharmacology Unit. He then served as the Chief Medical Officer at Mind Mental Health Technologies. Although he has incredible industry experience as well as a postgraduate education, he lacks in experience in the position of Chief Executive.

The company’s management team strength is thus unaffected by this announcement.

Categories
Management Team Change

New COO at New Leaf Brands – 05/11/2020

NLBIF – 0.397 MAIpsyc

New Leaf Brands announced this morning that they have hired Damon Michaels for the position of Chief Operating Officer. The company has not yet announced the fate of former COO and Director, Michael Connolly, although we believe the decision to be beneficial for the company.

Michael Connolly ranked poorly in our algorithm for experience in his position and in the industry. The new COO, Damon Michaels, has experience in both cannabis and mycology. Before joining New Leaf Brands he served as a managing executive at Ebbu, a cannabis research and technology firm. After Ebbu, he co-founded Mydecine Group, a mushroom research firm.

This move by New Leaf makes logical sense, as it recently signed a letter of intent to acquire a stake in Mydecine Group. Not only does this hire increase the strength of the company’s management team, it also increases their focus degree toward the psychedelic field. As a result, the company’s MAIpsyc score has increased slightly to 0.397.

The Mind Altering Index will be updated accordingly, and we will begin building a profile on Damon Michaels.


Join the MAIsubscriber Base for infrequent updates in your inbox. We don’t spam, and we often consolidate updates with score changes to limit the amount of emails that are sent.